Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Diethylcarbamazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diethylcarbamazine SCHEMBL37735 | 0.97 | KDM4E (0.94) | KDM4EALDH1A1LMNAMAPTALOX15 | |
| Diethylcarbamazine SCHEMBL4740035 | 0.90 | KDM4E (0.81) | KDM4EALDH1A1LMNAMAPTALOX15 | |
| Diethylcarbamazine SCHEMBL67289 | 0.82 | HTR1A (1.00) | KDM4EALDH1A1LMNAMAPTALOX15 | |
| Diethylcarbamazine SCHEMBL1819685 | 0.82 | HTR1A (1.00) | KDM4EALDH1A1LMNAMAPTALOX15 | |
| Diethylcarbamazine SCHEMBL10412471 | 0.81 | HTR1A (0.96) | KDM4EALDH1A1LMNAMAPTALOX15 | |
| Diethylcarbamazine SCHEMBL2319899 | 0.80 | HTR1A (0.79) | KDM4EALDH1A1LMNAMAPTALOX15 | |
| Diethylcarbamazine SCHEMBL2719699 | 0.79 | HTR1A (0.92) | KDM4EALDH1A1LMNAMAPTALOX15 | |
| SCHEMBL11096507 | 0.77 | HTR1A (0.89) | KDM4EALDH1A1LMNAMAPTALOX15 | |
| Citric Acid SCHEMBL11188422 | 0.77 | ALDH1A1 (0.62) | KDM4EALDH1A1LMNAMAPTALOX15 | |
| Citric Acid SCHEMBL4740036 | 0.77 | KDM4E (0.62) | KDM4EALDH1A1LMNAMAPTALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1588 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260007656-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ASTHMA, PNEUMONIA, BRONCHITIS, CYSTIC FIBROSIS, PULMONARY EDEMA, INTERSTITIAL LUNG DISEASE, SARCOIDOSIS, IDIOPATHIC PULMONARY FIBROSIS, ACUTE RESPIRATORY DISTRESS SYNDROME, PULMONARY ARTERIAL HYPERTENSION, ADN RESPIRATORY SYNCYTIAL VIRUS | REVERSPAH LLC (US) | 2026-01-08 | — | — | US | claimed |
| US-12440488-B2 | Methods and compositions for treating chronic obstructive pulmonary disease, asthma, pneumonia, bronchitis, cystic fibrosis, pulmonary edema, interstitial lung disease, sarcoidosis, idiopathic pulmonary fibrosis, acute respiratory distress syndrome, and pulmonary arterial hypertension | REVERSPAH LLC (US) | 2025-10-14 | — | — | US | claimed |
| US-20230346697-A1 | ANTIMICROBIAL AND ANTI-INFLAMMATORY COMPOSITIONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-02 | — | — | US | claimed |
| EP-4255418-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ASTHMA, PNEUMONIA, BRONCHITIS, CYSTIC FIBROSIS AND PULMONARY EDEMA | Reverspah LLC (US) | 2023-10-11 | — | — | EP | claimed |
| US-20230255969-A1 | TARGETING IMMUNE PATHOLOGIES INDUCED BY HIGHLY PATHOGENIC CORONAVIRUSES | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2023-08-17 | — | — | US | claimed |
| EP-4185286-A1 | TARGETING IMMUNE PATHOLOGIES INDUCED BY HIGHLY PATHOGENIC CORONAVIRUSES | National University of Singapore (SG) | 2023-05-31 | — | — | EP | claimed |
| US-20230013402-A1 | REGENERATING FUNCTIONS AND PHENOTYPES OF CONNECTIVE TISSUE THROUGH NPAS2 SUPPRESSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-01-19 | — | — | US | claimed |
| US-20220241368-A1 | PERCUTANEOUS ANTI-MICROBIOTA FORMULATIONS | HOFFMAN TECHNOLOGIES LLC | 2022-08-04 | — | — | US | claimed |
| EP-4025302-A1 | REGENERATING FUNCTIONS AND PHENOTYPES OF CONNECTIVE TISSUE THROUGH NPAS2 SUPPRESSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-07-13 | — | — | EP | claimed |
| WO-2022119916-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ASTHMA, PNEUMONIA, BRONCHITIS, CYSTIC FIBROSIS AND PULMONARY EDEMA. | REVERSPAH LLC (US) | 2022-06-09 | — | — | WO | claimed |
| EP-0357665-B1 | RAPIDLY DISSOLUBLE MEDICINAL DOSAGE UNIT AND METHOD OF MANUFACTURE | FUISZ TECHNOLOGIES LTD (US) | 1994-03-02 | — | — | EP | claimed |
| US-5277912-A | Sustained release capsule and formulations | ELI LILLY AND COMPANY (US) | 1994-01-11 | — | — | US | claimed |
| CN-1067810-A | Sustained-release capsule and preparation | LILLY CO ELI (US) | 1993-01-13 | — | — | CN | claimed |
| EP-0507629-A1 | Sustained release capsule and formulations for insertion into rumen | ELI LILLY AND COMPANY (US) | 1992-10-07 | — | — | EP | claimed |
| EP-0357665-A4 | RAPIDLY DISSOLUBLE MEDICINAL DOSAGE UNIT AND METHOD OF MANUFACTURE | — | 1990-09-05 | — | — | EP | claimed |
| EP-0357665-A1 | RAPIDLY DISSOLUBLE MEDICINAL DOSAGE UNIT AND METHOD OF MANUFACTURE. | FUISZ PHARMACEUTICAL LTD (US) | 1990-03-14 | — | — | EP | claimed |
| US-4855326-A | MELT SPINNING WATER SOLUBLE FIBER CARRIERS | FUISZ PHARMACEUTICAL LTD. (US) | 1989-08-08 | — | — | US | claimed |
| WO-1988008298-A1 | RAPIDLY DISSOLUBLE MEDICINAL DOSAGE UNIT AND METHOD OF MANUFACTURE | FUISZ RICHARD C (US) | 1988-11-03 | — | — | WO | claimed |
| US-4177256-A | Osmotic bursting drug delivery device | ALZA CORPORATION (US) | 1979-12-04 | — | — | US | claimed |
| US-4147785-A | Method for the treatment of onchocerciasis | Dobbie, Graham J. (US) | 1979-04-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260007656-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ASTHMA, PNEUMONIA, BRONCHITIS, CYSTIC FIBROSIS, PULMONARY EDEMA, INTERSTITIAL LUNG DISEASE, SARCOIDOSIS, IDIOPATHIC PULMONARY FIBROSIS, ACUTE RESPIRATORY DISTRESS SYNDROME, PULMONARY ARTERIAL HYPERTENSION, ADN RESPIRATORY SYNCYTIAL VIRUS | PDE12, PDE3B, PDE5A | MEN1 3692/4885KDM4E 4018/4885ALDH1A1 1973/4885 |
| US-20230013402-A1 | REGENERATING FUNCTIONS AND PHENOTYPES OF CONNECTIVE TISSUE THROUGH NPAS2 SUPPRESSION | PER2, NCBP2, NOTCH1 | MEN1 2861/4885KDM4E 2746/4885ALDH1A1 4080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.